GlassScriptPhysician profile
Amy Sullivan
NPI 1275145369
$2,448.74
in general payments reported to CMS, 2019-2025
19 companies · $1,011 in 2025
The $1,011 reported for 2025 was more than what 85% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $33.91 · 2022: $330 · 2023: $407 · 2024: $667 · 2025: $1,011.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,084.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,084.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $682.19 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $291.77 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $291.56 | 2022-2025 | Ultomiris, Strensiq |
| Eisai INC. | $182.30 | 2023-2024 | |
| Lilly USA, LLC | $169.21 | 2022-2025 | Kisunla, Amyvid |
| Amgen INC. | $116.07 | 2022-2025 | Evenity, Prolia, Repatha |
| Radius Health, INC. | $115.29 | 2023-2024 | Tymlos |
| Argenx US, INC. | $109.12 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Takeda Pharmaceuticals U.S.A., INC. | $105.83 | 2025 | Hyqvia |
| Ucb, INC. | $68.82 | 2025 | Rystiggo |
| Pfizer INC. | $65.79 | 2024-2025 | |
| Kyowa Kirin, INC. | $62.82 | 2023 | Crysvita |
| Lundbeck LLC | $46.23 | 2021-2023 | Vyepti |
| Avanir Pharmaceuticals, INC. | $36.69 | 2021-2022 | |
| Livanova USA, INC. | $35.08 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $23.23 | 2024 | Linq II |
| Neurelis, INC. | $18.15 | 2024 | Valtoco |
| Astrazeneca Pharmaceuticals LP | $14.91 | 2024 | Andexxa |
| Cycle Pharmaceuticals INC | $13.68 | 2025 | Tascenso Odt, Bafiertam |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Sullivan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.